Pfizer PFE

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Pfizer backs out of funding Puma cancer drug trials

      Headlines

      Tue, 22 Jul 2014

      Pfizer ( PFE +0.5% ) amends its license agreement ..... mutation. Under the terms of the amendment, Pfizer will not fund the legacy clinical trials and the royalty Puma is obligated to pay Pfizer is fixed at low- to mid-teens. Originally

    2. “Tax Reform is Impossible – Until it is Inevitable”

      Headlines

      Tue, 22 Jul 2014

      prompted U.S. businesses to move operations (and jobs) overseas. This year Pfizer made a bid (since withdrawn) to take over AstraZeneca in part for the taxes Pfizer would save by moving its headquarters from the United States to London. Last

    3. HIV combo therapy candidate fails Phase 3

      Headlines

      Tue, 22 Jul 2014

      trial comparing a once-daily dose of Solzentry ( maraviroc ) ( PFE +0.7% ) with Prezista (darunavir) ( JNJ +1.1% ) and ..... was established in late 2009 by Glaxo ( GSK -0.1% ) and Pfizer . ViiV Healthcare CSO and CMO Dr. John Pottage says, "Athough

    4. New Morningstar Analyst Report for AbbVie Inc

      Stock Reports

      Tue, 22 Jul 2014

      penetrate these markets.The new competitive RA threat from Pfizer 's Xeljanz will not likely take much share from Humira ..... Humira. Key emerging competitive threats to Humira include Pfizer 's oral RA drug Xeljanz, cheaper generic versions of

    5. Attractive tax inversion targets remain, analysts say

      Headlines

      Mon, 21 Jul 2014

      puts limits on the maneuvers. Stryker (NYSE: SYK ) has been mentioned as a potential suitor for Smith& Nephew. Pfizer (NYSE: PFE ) may make another run at AstraZeneca (NYSE: AZN ) after the end of the cool-off period. Post your comment

    6. CORRECTED-Shire, AbbVie to announce $53 billion merger by Friday -sources

      Headlines

      Thu, 17 Jul 2014

      (Corrects 6th paragraph to show Pfizer 's failed bid for AstraZeneca happened in May not June)

    7. Xalkori: Pfizer's Lung Cancer Drug Might Get A Future Boost In Sales

      Headlines

      Thu, 17 Jul 2014

      By The Panama City Investor : It is no secret that Pfizer (NYSE: PFE ) has had a rocky first half this year. The difficulties ..... a 10% increase in operational revenues. (source: Pfizer 's Q1 2014 report) There are three main contributors

    8. Why Pfizer Could Beat This Sector Peer

      Headlines

      Wed, 16 Jul 2014

      By Team Money Research : Pfizer Background Pfizer (NYSE: PFE ) was founded in 1849 and is headquartered in New York. The company's Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians

    9. Positive top-line results for BeneFIX

      Headlines

      Wed, 16 Jul 2014

      In a Phase 3 clinical tria l comparing Pfizer 's ( PFE +1.2% ) BeneFIX Coagulation Factor IX (Recombinant) as a treatment for patients with moderately severe-to-severe hemophilia

    10. Pfizer buys injectables maker

      Headlines

      Wed, 16 Jul 2014

      Pfizer ( PFE +1.1% ) acquires privately-held InnoPharma for an upfront payment of $225M and up to $135M in contingent milestone payments

    « Prev12345Next »
    Content Partners